22 related articles for article (PubMed ID: 16483162)
1. Seasonal expressions of VEGF and its receptors VEGFR1 and VEGFR2 in the prostate of the wild ground squirrels (Spermophilus dauricus).
Yao Y; Xie W; Chen D; Han Y; Yuan Z; Zhang H; Weng Q
Eur J Histochem; 2021 Mar; 65(2):. PubMed ID: 33764018
[TBL] [Abstract][Full Text] [Related]
2. The Role of Lactate Metabolism in Prostate Cancer Progression and Metastases Revealed by Dual-Agent Hyperpolarized
Bok R; Lee J; Sriram R; Keshari K; Sukumar S; Daneshmandi S; Korenchan DE; Flavell RR; Vigneron DB; Kurhanewicz J; Seth P
Cancers (Basel); 2019 Feb; 11(2):. PubMed ID: 30813322
[TBL] [Abstract][Full Text] [Related]
3. Co-expression of HIF-1α, MDR1 and LAPTM4B in peripheral blood of solid tumors.
Rehman Z; Fahim A; Bhatti A; Sadia H; John P
PeerJ; 2019; 7():e6309. PubMed ID: 30746305
[TBL] [Abstract][Full Text] [Related]
4. The association of HIF-1α expression with clinicopathological significance in prostate cancer: a meta-analysis.
Huang M; Du H; Zhang L; Che H; Liang C
Cancer Manag Res; 2018; 10():2809-2816. PubMed ID: 30174456
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Hypoxia Inducible Factor-1α and Glucose Transporter-1 Expression in Non Melanoma Skin Cancer: An Immunohistochemical Study.
Seleit I; Bakry OA; Al-Sharaky DR; Ragab RAA; Al-Shiemy SA
J Clin Diagn Res; 2017 Jun; 11(6):EC09-EC16. PubMed ID: 28764171
[TBL] [Abstract][Full Text] [Related]
6. Assessing Prostate Cancer Aggressiveness with Hyperpolarized Dual-Agent 3D Dynamic Imaging of Metabolism and Perfusion.
Chen HY; Larson PEZ; Bok RA; von Morze C; Sriram R; Delos Santos R; Delos Santos J; Gordon JW; Bahrami N; Ferrone M; Kurhanewicz J; Vigneron DB
Cancer Res; 2017 Jun; 77(12):3207-3216. PubMed ID: 28428273
[TBL] [Abstract][Full Text] [Related]
7. The role of hypoxia-inducible factor 1α in determining the properties of castrate-resistant prostate cancers.
Ranasinghe WK; Xiao L; Kovac S; Chang M; Michiels C; Bolton D; Shulkes A; Baldwin GS; Patel O
PLoS One; 2013; 8(1):e54251. PubMed ID: 23342109
[TBL] [Abstract][Full Text] [Related]
8. Morphoproteomic confirmation of a constitutively activated mTOR pathway in high grade prostatic intraepithelial neoplasia and prostate cancer.
Brown RE; Zotalis G; Zhang PL; Zhao B
Int J Clin Exp Pathol; 2008 Jan; 1(4):333-42. PubMed ID: 18787612
[TBL] [Abstract][Full Text] [Related]
9. Microvessel density as a molecular marker for identifying high-grade prostatic intraepithelial neoplasia precursors to prostate cancer.
Sinha AA; Quast BJ; Reddy PK; Lall V; Wilson MJ; Qian J; Bostwick DG
Exp Mol Pathol; 2004 Oct; 77(2):153-9. PubMed ID: 15351240
[TBL] [Abstract][Full Text] [Related]
10. [Expression of hypoxia-inducible factor 1 alpha and vascular endothelial growth factor in prostate cancer and its significance].
Wang L; Chen ZJ; Wang QT; Cao WF; Jian Y; Wang SX; Zhang BH
Zhonghua Nan Ke Xue; 2006 Jan; 12(1):57-9. PubMed ID: 16483162
[TBL] [Abstract][Full Text] [Related]
11. The expression of hypoxia-inducible factor-1alpha (HIF-1alpha) and angiogenesis markers in hyperplastic and malignant prostate tissue.
Lekas A; Lazaris AC; Deliveliotis C; Chrisofos M; Zoubouli C; Lapas D; Papathomas T; Fokitis I; Nakopoulou L
Anticancer Res; 2006; 26(4B):2989-93. PubMed ID: 16886625
[TBL] [Abstract][Full Text] [Related]
12. Expression of hypoxia-inducible factor 1alpha in human normal, benign, and malignant prostate tissue.
Du Z; Fujiyama C; Chen Y; Masaki Z
Chin Med J (Engl); 2003 Dec; 116(12):1936-9. PubMed ID: 14687488
[TBL] [Abstract][Full Text] [Related]
13. Finasteride effects on hypoxia and angiogenetic markers in benign prostatic hyperplasia.
Lekas AG; Lazaris AC; Chrisofos M; Papatsoris AG; Lappas D; Patsouris E; Deliveliotis C
Urology; 2006 Aug; 68(2):436-41. PubMed ID: 16904480
[TBL] [Abstract][Full Text] [Related]
14. Human telomerase reverse transcriptase expression correlates with vascular endothelial growth factor-promoted tumor cell proliferation in prostate cancer.
Tang J; Wang Z; Li X; Li J; Shi H
Artif Cells Blood Substit Immobil Biotechnol; 2008; 36(2):83-93. PubMed ID: 18437586
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
